Felypressin

Names
IUPAC name 1-[19-Amino-13,16-dibenzyl-10-(2-carbamoyl-ethyl)-7-carbamoylmethyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaaza-cycloeicosane-4-carbonyl]-pyrrolidine-2-carboxylic acid [5-amino-1-(carbamoylmethyl-carbamoyl)-pentyl]-amide
Identifiers
CAS Number	56-59-7 Y
3D model (JSmol)	Interactive image
ChEBI	CHEBI:60564 Y
ChEMBL	ChEMBL1697764 N
ChemSpider	16736539 Y
DrugBank	DB00093 Y
ECHA InfoCard	100.000.257
PubChem CID	5956
UNII	17N2918V6G Y
CompTox Dashboard (EPA)	DTXSID6048599
InChI InChI=1S/C46H65N13O11S2/c47-18-8-7-14-29(40(64)52-23-38(51)62)54-45(69)35-15-9-19-59(35)46(70)34-25-72-71-24-28(48)39(63)55-31(20-26-10-3-1-4-11-26)43(67)56-32(21-27-12-5-2-6-13-27)42(66)53-30(16-17-36(49)60)41(65)57-33(22-37(50)61)44(68)58-34/h1-6,10-13,28-35H,7-9,14-25,47-48H2,(H2,49,60)(H2,50,61)(H2,51,62)(H,52,64)(H,53,66)(H,54,69)(H,55,63)(H,56,67)(H,57,65)(H,58,68)/t28-,29-,30-,31-,32-,33-,34-,35-/m0/s1 Y Key: SFKQVVDKFKYTNA-DZCXQCEKSA-N Y InChI=1/C46H65N13O11S2/c47-18-8-7-14-29(40(64)52-23-38(51)62)54-45(69)35-15-9-19-59(35)46(70)34-25-72-71-24-28(48)39(63)55-31(20-26-10-3-1-4-11-26)43(67)56-32(21-27-12-5-2-6-13-27)42(66)53-30(16-17-36(49)60)41(65)57-33(22-37(50)61)44(68)58-34/h1-6,10-13,28-35H,7-9,14-25,47-48H2,(H2,49,60)(H2,50,61)(H2,51,62)(H,52,64)(H,53,66)(H,54,69)(H,55,63)(H,56,67)(H,57,65)(H,58,68)/t28-,29-,30-,31-,32-,33-,34-,35-/m0/s1 Key: SFKQVVDKFKYTNA-DZCXQCEKBI
SMILES NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@H]4NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@@H](N)CSSC4)CC(N)=O
Properties
Chemical formula	C46H65N13O11S2
Molar mass	1040.22 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). N verify (what is YN ?) Infobox references

Felypressin is a non-catecholamine vasoconstrictor that is chemically related to vasopressin, the posterior pituitary hormone. It is added to some local anaesthetics such as prilocaine in a concentration of 0.03 IU/ml. Felypressin is a Vasopressin 1 agonist, and will thus have effects at all Arginine vasopressin receptor 1As. It will, however, have its main physiological effects on vascular SMC's due to the form in which it is administered.

V1 receptors are found in various sites around the body. The major points include the CNS, Liver, Anterior Pituitary, Muscle (both vascular and non-vascular smooth muscle), and Platelets (CLAMP).

Another example of a V1 agonist is terlipressin - which is used in oesophageal varices.

References

• "Vasopressin analogues and treatments", Prof Buckingham, Imperial College School of Medicine (ICSM) - adapted by JHPatel